Investing.com -- Capricor Therapeutics (NASDAQ:CAPR) stock plunged over 15% Monday after controversial former pharmaceutical executive Martin Shkreli identified the company as a short target.

Shkreli predicted the stock would settle at approximately $2 per share, a significant drop from its current level. The stock ...

Shares of Capricor Therapeutics (CAPR) slumped 17% on Monday morning after former biotech executive and businessman Martin ...

Martin Shkreli, former hedge fund manager known as Pharma Bro, scolded finance personalities for not understanding accounting ...

Many big tech companies, including startups, are foraying into the emerging field of quantum computing. Out of the 300 quantum computing patents issued in 2025, two companies have received the most.

WASHINGTON — The Supreme Court on Monday rejected an appeal from Martin Shkreli, who was once dubbed “Pharma Bro” after jacking up the price of a lifesaving drug. Shkreli appealed an order to return ...

Even prison bars can’t stop the infamous “pharma bro.” Martin Shkreli, the disgraced pharmaceutical exec who gained notoriety for inflating the price of a lifesaving anti-infection drug, is serving a ...

JFRD responding to fire at airport parking garage. Get ready for some fabulous deals for when you're on the go, your beauty routine and in the kitchen. The Supreme Court is seen on Monday, Oct. 7, ...